News
When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...
DOI: 10.1016/S1474-4422 (25)00199-1 Individual immune cells genetically altered CIDP is an autoimmune disease in which the immune system's B-cells attack the peripheral nervous system.
CIDP is an autoimmune disease in which the immune system's B-cells attack the peripheral nervous system. In the current study, the CAR CD19 T-cell therapy was used to combat these rogue B-cells.
People living with autoimmune diseases face nearly twice the risk of developing persistent mental health disorders like depression, anxiety, and bipolar disorder, according to a massive UK-based study ...
Experimental treatment could offer a safer, cheaper alternative to CAR-T-cell therapies for disorders such as lupus.
Misbehaving T cells light up long before Parkinson’s symptoms show, zeroing in on vulnerable brain proteins. Their early ...
The prevalence of autoimmune disease patients with a mental health disorder is almost twice the number of patients without, suggesting there is a link between inflammation and conditions such as ...
Individual immune cells genetically altered CIDP is an autoimmune disease in which the immune system’s B-cells attack the peripheral nervous system. In the current study, the CAR CD19 T-cell therapy ...
The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) subcutaneous (SC) injection to treat chronic inflammatory demyelinating polyneuropathy (CIDP).
Hosted on MSN20d
Restoring mobility: Rare autoimmune disease successfully treated with CAR T-cell therapy - MSNCIDP is an autoimmune disease in which the immune system's B-cells attack the peripheral nervous system. In the current study, the CAR CD19 T-cell therapy was used to combat these rogue B-cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results